Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Webb

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 1997
Activating mutations for the met tyrosine kinase receptor in human cancerM Jeffers, L Schmidt, N Nakaigawa, et al.
Oncogene|November 3, 1998
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasisC P Webb, G A Taylor, M Jeffers, et al.
Cancer Research|February 10, 2000
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic networkC P Webb, C D Hose, S Koochekpour, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2001
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathwaysN S Duesbery, J Resau, C P Webb, et al.
The American Journal of Pathology|August 4, 2001
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factorG A Gmyrek, M Walburg, C P Webb, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2001
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinaseK A Furge, D Kiewlich, P Le, et al.
Science (New York, N.Y.)|May 23, 1998
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factorN S Duesbery, C P Webb, S H Leppla, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 1997
Activating mutations for the met tyrosine kinase receptor in human cancerM Jeffers, L Schmidt, N Nakaigawa, et al.
Oncogene|November 3, 1998
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasisC P Webb, G A Taylor, M Jeffers, et al.
Cancer Research|February 10, 2000
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic networkC P Webb, C D Hose, S Koochekpour, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2001
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathwaysN S Duesbery, J Resau, C P Webb, et al.
The American Journal of Pathology|August 4, 2001
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factorG A Gmyrek, M Walburg, C P Webb, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2001
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinaseK A Furge, D Kiewlich, P Le, et al.
Science (New York, N.Y.)|May 23, 1998
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factorN S Duesbery, C P Webb, S H Leppla, et al.
Pageof 2